Peptide Reference
Sermorelin
Sermorelin Acetate
A growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce and secrete growth hormone. FDA-approved for diagnosing and treating growth hormone deficiency in children.
Status
approved
Category
growth hormone
Typical cost
$300-500/month (prescription)
Mechanism
Binds to GHRH receptors in the pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. Preserves the natural feedback mechanisms, reducing risk of excessive GH production.
Potential benefits
- Increased growth hormone
- Improved body composition
- Better sleep quality
- Enhanced recovery
- Increased bone density
- Improved immune function
- FDA-approved
- Natural GH pulsatility
- No GH shutdown
- Diagnostic utility
- Well-studied
Reported side effects
- Injection site reactions
- Headache
- Flushing
- Dizziness
- Sleepiness
- Nausea
- Short half-life
Common dosing references
subcutaneous
0.2-0.3mg · Daily at bedtime
3-6 months
Research notes
Sermorelin in GH deficiency
1997
FDA approval based on effective stimulation of GH release with good safety profile
Sermorelin GH stimulation
1997
FDA approval based on efficacy in GH deficiency
Regulatory and sourcing notes
FDA-approved for growth hormone deficiency diagnosis and treatment. Available by prescription.
Prescription only. Compounded versions available from specialty pharmacies.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides